SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine...
NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...
NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The “ Make it VIZZable ” campaign features SJP...
NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million...
SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive...
NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...
SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus...
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine...